- Home
- MWC vs AKBA Comparison
MWC vs AKBA Comparison
Compare MWC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MWC | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 251.0M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MWC | AKBA |
|---|---|---|
| Price | $3.32 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 55.6K | ★ 6.1M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.28 | $0.82 |
| 52 Week High | $4.20 | $4.08 |
Technical Indicators
Market Signals| Indicator | MWC | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 72.41 |
| Support Level | N/A | $1.32 |
| Resistance Level | $3.89 | $1.56 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 5.26 | 92.55 |
Price Performance
Historical ComparisonAbout AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.